Dr Reddys Laboratories (RDY) Cash & Equivalents (2012 - 2026)

Dr Reddys Laboratories' Cash & Equivalents history runs 15 years deep, the most recent figure standing at $168.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 0.66% year-over-year to $168.1 million; the TTM figure through Mar 2026 stood at $168.1 million (down 0.66% YoY), while the FY2026 annual figure was $164.0 million, down 4.65% from the prior year.
• Cash & Equivalents was $168.1 million for Q1 2026 at Dr Reddys Laboratories, roughly flat from $167.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $197.5 million in Q1 2022 to a low of $69.9 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $128.6 million across 5 years, with a median of $127.6 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents slumped 64.41% in 2023, then soared 100.14% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $186.3 million in 2022, then slumped by 62.47% to $69.9 million in 2023, then grew by 21.38% to $84.9 million in 2024, then soared by 97.17% to $167.3 million in 2025, then rose by 0.48% to $168.1 million in 2026.
• The last three Cash & Equivalents figures came in at $168.1 million (Q1 2026), $167.3 million (Q3 2025), and $170.5 million (Q2 2025), per Business Quant data.